Madrigal Pharmaceuticals (MDGL) Long-Term Deferred Tax (2016 - 2023)

Madrigal Pharmaceuticals (MDGL) has 7 years of Long-Term Deferred Tax data on file, last reported at $383.2 million in Q4 2023.

• Long-Term Deferred Tax for Q4 2023 came in at $383.2 million, up 41.36% year-over-year; the trailing twelve-month figure through Dec 2023 was $383.2 million (up 41.36% YoY), and the FY2023 annual result was $383.2 million, up 41.36% from the prior year.
• Long-Term Deferred Tax rose to $383.2 million in Q4 2023 per MDGL's latest filing, from $271.1 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $383.2 million in Q4 2023 and troughed at $14000.0 in Q4 2020.
• A 4-year average of $180.1 million and a median of $168.5 million in 2019 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2019 and 2020: Long-Term Deferred Tax soared 69.08% in 2019, then sank 99.98% in 2020.
• A 4-year view of Long-Term Deferred Tax shows it stood at $65.9 million in 2019, then slumped by 99.98% to $14000.0 in 2020, then jumped by 1936385.71% to $271.1 million in 2022, then soared by 41.36% to $383.2 million in 2023.
• Business Quant data shows MDGL's Long-Term Deferred Tax at $383.2 million in Q4 2023, $271.1 million in Q4 2022, and $14000.0 in Q4 2020.